-1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
-1 	|BT| (S (NP (NN p53) (NN activation) (NN CRC) (NN cell)) (VP (VBD interfered) (NP (JJ IL-6-induced) (NN invasion) (NN migration)) (PP (IN via) (NP (JJ miR-34a-dependent) (NN downregulation) (NN IL6R) (NN expression))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 201:D12.644.276.374.465.224|ES| 12:1 19:1 94:1 115:1 225:1 245:1 514:1 595:1 596:1 620:1 681:1 682:1 683:1 684:1
-1 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1
-1 	|BT| (NP (NP (NN PURPOSE) (CC AND) (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (NP (NP (DT The) (JJ molecular) (NN mechanism) (NN p14ARF) (NN gene)) (ADJP (JJ altered) (SBAR (S (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (VP (NN complex) (ADJP (JJ unclear)))))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 204:E05.581.500 205:E05.581.500|ES| 9:1 10:1 14:1 18:1 19:1 94:1 104:1 161:1 162:1 328:1 329:1 443:1 687:1 688:1 689:1 690:1 691:1 692:1 693:1 694:1 695:1
-1 	|BT| (NP (NP (NP (NN PURPOSE) (: :)) (NN IFITM3) (, ,) (JJ IFN-inducible) (NN gene)) (, ,) (NP (VBN overexpressed) (JJ human) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 9:1 17:1 18:1 19:1 25:1 36:1 104:1 687:1 696:1 697:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (NN MYC) (NN oncogene)) (ADVP (RB frequently)) (VP (VBN overexpressed) (NP (NN prostate) (NN cancer)))) |ET| |BS||ES| 18:1 19:1 24:1 25:1 77:1 104:1 472:1 687:1 691:1 698:1
-1 	|BT| (NP (NP (NN Regulation) (NN tumor) (NN suppressor) (NN homeogene) (NN Cdx2) (NN HNF4alpha) (JJ intestinal) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 101:C04.588.274.476.411 142:I01.880.604 206:G05.360.340.024.340.375.249|ES| 7:1 18:1 19:1 109:1 123:1 213:1 699:1 700:1 701:1
-1 	|BT| (FRAG (NP (NNS Results)) (VBP show) (NP (NN KLF9) (JJ haploinsufficient) (NN suppressor) (NN colon) (NN tumorigenesis) (NN Apc)) (-LRB- -LRB-) (NP (NP (NP (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN part)) (, ,) (NP (NP (NN repression) (NN ISG15) (NN latter) (POS 's)) (JJ antiapoptotic) (NN function))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 207:G05.365.590.029.530.587 208:F01.393.821|ES| 2:1 10:1 14:1 19:1 33:1 52:1 78:1 113:1 280:1 429:1 451:1 461:1 700:1 702:1 703:1 704:1 705:1 706:1 707:1 708:1 709:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (VP (ADVP (RB Herein)) (VB provide) (NP (JJ new) (NP (NN evidence) (JJ transcriptional) (NN regulation)) (NN Notch) (NN PEA3) (NN breast) (NN cancer)))) |ET| |BS|142:I01.880.604 209:G02.111.087.847|ES| 18:1 19:1 23:1 38:1 104:1 256:1 428:1 438:1 559:1 710:1 711:1 712:1 713:1
-1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (PP (IN In) (NP (NN CRC) (NN cell) (NN line))) (, ,) (VP (VBP mimic) (NP (NN miR-221) (NN miR-222) (VBD activated) (NN NF-kappaB) (NN STAT3)) (, ,) (NP (VBG increasing) (NN expression) (NN miR-221) (NN miR-222))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 82:D12.644.360.024.342.300 94:A11.251.210 210:D12.776.260.600|ES| 2:1 19:1 94:1 104:1 115:1 140:1 141:1 163:1 244:1 245:1 251:1 264:1 567:1 710:1 714:1 715:1
-1 	|BT| (S (NP (NN Sil) (NN gene) (NN expression) (NN lung) (NN cancer)) (VP (VBD correlated) (NP (NN expression) (JJ several) (NN kinetochore) (NN check-point) (NN gene) (JJ histopathologic) (JJ mitotic) (NN index)))) |ET| |BS|155:G05.355.310 211:A11.284.430.106.279.345.190.160.165.500 212:E01.370.225.500.385.500|ES| 9:1 18:1 19:1 115:1 262:1 328:1 446:1 716:1 717:1 718:1 719:1 720:1 721:1
-1 	|BT| (S (NP (NN Silencing) (NN MLH1)) (VP (ADVP (RB frequently)) (VBN seen) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 213:F02.830.816.964|ES| 17:1 18:1 19:1 698:1 722:1 723:1 724:1 725:1
-1 	|BT| (S (ADVP (RB Similarly)) (, ,) (NP (NN treatment) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line) (NN hypomethylating) (NN agent)) (VP (VBZ induces) (NP (NP (JJ differentiation-related) (NN gene)) (, ,) (PP (VBG including) (NP (NN CDX1)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 94:A11.251.210|ES| 2:1 9:1 18:1 19:1 36:1 94:1 113:1 214:1 264:1 546:1 561:1 726:1 727:1 728:1 729:1 730:1
-1 	|BT| (S (NP (JJ Sonic) (NN hedgehog) (NN inhibitor)) (VP (VBP prevent) (NP (JJ colitis-associated) (NN cancer)) (FRAG (IN via) (NP (VBN orchestrated) (NN mechanism) (NN IL-6)) (: /) (NP (NP (NN gp130) (NN inhibition)) (, ,) (NP (NN 15-PGDH) (NN induction)) (, ,) (NP (NN Bcl-2) (NN abrogation)) (, ,) (NP (NN tumorsphere) (NN inhibition)))))) |ET| |BS|43:F01.145.544 53:C06.405.205.265 54:G05.360.340.024.340.375.500.791.150 201:D12.644.276.374.465.224 214:B01.050.150.900.649.473.376|ES| 2:1 18:1 19:1 103:1 133:1 158:1 162:1 380:1 410:1 596:1 731:1 732:1 733:1 734:1 735:1 736:1 737:1 738:1
-1 	|BT| (S (NP (NN SPDEF)) (VP (VP (VBD inhibited) (NP (NN expression) (JJ beta-catenin-target) (NN gene) (NN mouse) (NN colon) (NN tumor))) (, ,) (VP (VBD interacted) (NP (NP (NN beta-catenin) (NN block) (JJ transcriptional) (NN activity)) (NP (NN CRC) (NN cell) (NN line))) (, ,) (S (VP (VBG resulting) (NP (JJR lower) (NN level) (NN cyclin) (NN D1) (NN c-MYC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 94:A11.251.210 122:C14.280.383 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100|ES| 2:1 7:1 9:1 19:1 52:1 60:1 94:1 113:1 115:1 117:1 245:1 249:1 264:1 365:1 384:1 399:1 559:1 625:1 739:1 740:1 741:1 742:1 743:1 744:1
-1 	|BT| (S (NP (JJ Stable) (NN transfection) (NN Ha-ras) (JJ human) (NN colon) (NN cancer) (NN line) (NN CaCo2)) (VP (VBP result) (NP (JJ morphologic) (NN differentiation) (JJ small) (NN bowel) (NN phenotype)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 216:Z01.107.084.900.425 217:E05.393.350.810 218:A03.556.124.684|ES| 18:1 19:1 36:1 101:1 113:1 215:1 236:1 264:1 745:1 746:1 747:1 748:1 749:1 750:1 751:1
-1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
-1 	|BT| (S (NP (DT The) (NN adhesion) (NN molecule) (NN L1CAM)) (VP (VBZ mediates) (S (NP (NN chemoresistance) (NN migration) (NN tumor) (NN cell) (JJ elevated) (NN CRC) (NN tissue)) (NP (VBN associated) (JJ metastatic) (NN spread) (JJ poor) (NN prognosis) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 98:A10 113:C04.697.650 159:I01.880.735.634 163:E01.789 221:D12.776.395.550.200.250.520.578 222:D12.776.395.550.200|ES| 7:1 19:1 94:1 120:1 169:1 180:1 182:1 245:1 272:1 337:1 514:1 544:1 545:1 691:1 753:1 754:1 755:1 756:1 757:1
-1 	|BT| (S (NP (DT The) (NN analysis) (JJ clinical) (JJ characteristic)) (VP (VBD showed) (SBAR (S (NP (NN miR-141)) (ADVP (RB significantly)) (VP (VBD downregulated) (NP (NN tissue) (NN cell) (NN line) (JJ pancreatic) (NN cancer))))))) |ET| |BS|94:A11.251.210 98:A10|ES| 18:1 19:1 84:1 94:1 124:1 132:1 264:1 272:1 336:1 426:1 463:1 467:1 661:1 691:1
-1 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1
-1 	|BT| (S (NP (DT The) (NN CDX2) (NN expression) (JJ gastric) (NN cancer)) (ADVP (RB also)) (ADVP (RB inversely)) (VP (VBD correlated) (NP (NN expression) (JJ gastric) (NN mucin)))) |ET| |BS|72:D12.776.395.560.631.100|ES| 5:1 18:1 19:1 86:1 114:1 115:1 209:1 418:1 446:1 691:1
-1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
-1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
-1 	|BT| (FRAG (NP (NP (DT The) (NN level) (NN miR-221) (NN miR-222)) (RRC (ADVP (RB well)) (NP (NP (NN RelA)) (, ,) (NP (NN STAT3)) (, ,) (NP (NP (NN PDLIM2) (NNS mRNAs)) (VP (VBN measured) (NP (CD 57) (JJ paired) (NN CRC) (JJ adjacent) (JJ nontumor) (NN tissue) (NN patient)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544 228:E05.978|ES| 2:1 19:1 120:1 126:1 140:1 141:1 245:1 249:1 250:1 251:1 272:1 326:1 445:1 447:1 691:1 787:1 788:1 789:1 790:1
-1 	|BT| (NP (NP (DT The) (NN role) (NN KCNQ1) (NN mouse) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 31:1 36:1 52:1 183:1 691:1 791:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (S (NP (NN K-sam) (NN overexpression)) (VP (VBN associated) (NP (JJ malignant) (NN phenotype) (JJ undifferentiated) (NN type) (NN stomach) (NN cancer)))) (, ,) (NP (JJ infiltrative) (NN growth) (NN metastasis)))))) |ET| |BS|45:G07.700.320.249 80:G05.695 113:C04.697.650 231:C04.557.465.625.600.380.590 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 101:1 102:1 152:1 169:1 236:1 543:1 792:1 796:1 801:1 802:1 803:1 804:1 805:1 806:1
-1 	|BT| (S (S (NP (DT This) (JJ K-Ras) (NN tumor) (NN phenotype)) (VP (VBN associated) (VP (VBD attenuated) (NP (NN signaling) (NN MAPK) (NN pathway))))) (, ,) (NP (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBG expressing) (NP (NP (JJ mutant) (NN K-Ras) (JJ hypersensitive) (NN inhibition) (NN Raf)) (, ,) (NP (NN Mek))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 80:G05.695 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565|ES| 2:1 7:1 13:1 18:1 19:1 36:1 94:1 103:1 113:1 169:1 195:1 236:1 383:1 807:1 808:1 809:1 810:1 811:1 812:1 813:1 814:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NP (JJ first) (JJ quantitative) (NN analysis) (JJ discrete) (NN CRKI) (NN CRKII) (NN protein) (NNS isoforms)) (SBAR (S (NP (JJ human) (NN lung) (NN tumor)) (VP (VBZ provides) (NP (NN evidence) (NN C-CRK) (NN proto-oncogene)))))) (VP (MD may) (VP (VB foment) (NP (JJ aggressive) (NN phenotype) (NN lung) (NN cancer)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 162:F01.145.126.125 235:G05.360.340.024.340.375.500.791 236:D12.644.360.024.318 237:C04.588.894.797.520 238:D12.776.800|ES| 4:1 7:1 18:1 19:1 36:1 38:1 131:1 236:1 328:1 491:1 538:1 563:1 661:1 807:1 815:1 816:1 817:1 818:1 819:1 820:1 821:1 822:1 823:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
-1 	|BT| (S (S (S (VP (TO To) (VP (VB understand) (NP (NN miR-141))))) (VP (VBZ mediates) (NP (NN phenotype) (JJ pancreatic) (NN cancer) (NN cell)))) (S (, ,) (NP (NNS bioinformatics) (NN tool)) (VP (VBN used) (VP (VBP identify) (NP (NN MAP4K4) (JJ potential) (NN target) (NN miR-141)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 80:G05.695 239:F02.463.188.357 240:H01.158.273.180|ES| 2:1 18:1 19:1 94:1 160:1 236:1 463:1 465:1 467:1 476:1 755:1 827:1 828:1 829:1 830:1 831:1 832:1
-1 	|BT| (FRAG (PP (TO To) (NP (VB investigate) (NP (NP (NN role) (NN KCNQ1) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN measured) (NN protein) (NN level) (NN KCNQ1) (NN immunohistochemistry) (NN tissue) (NNS microarrays)) (VP (VBG containing) (NP (NP (NN sample) (NN CRC) (NN patient) (NN liver) (NN metastasis)) (VP (VBN undergone) (NP (JJ hepatic) (NN resection))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 228:E05.978 241:D12.776.157.530.400.600.900.124.249.500 242:A03.620|ES| 2:1 4:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 120:1 128:1 245:1 249:1 272:1 286:1 459:1 789:1 791:1 806:1 828:1 833:1 834:1 835:1 836:1 837:1 838:1
-1 	|BT| (NP (NP (NP (JJ Transient) (JJ stable) (NN overexpression) (NN mir-660)) (S (VP (VBG using) (S (NP (NN miRNA)) (VP (VBP mimic) (SBAR (S (NP (VBN reduced) (NP (NN migration)) (, ,) (NP (NN invasion)) (, ,) (NP (NN proliferation) (NN property))) (VP (VBD increased) (NP (NP (NN apoptosis) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN cell)) (PRN (-LRB- -LRB-) (NP (NP (NN NCI-H460)) (, ,) (NP (NN LT73)) (, ,) (NP (NN A549))) (-RRB- -RRB-)))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 120:I01.409.418.750.600.480.150 184:D13.150.650.319|ES| 2:1 8:1 10:1 12:1 14:1 18:1 19:1 47:1 89:1 94:1 152:1 299:1 328:1 350:1 360:1 363:1 364:1 373:1 452:1 514:1 567:1 620:1 839:1 840:1 841:1 842:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD aimed) (VP (VB investigate) (SBAR (IN whether) (S (NP (NN Notch1) (NN signaling)) (VP (VBZ contributes) (NP (NN carcinogenesis) (JJ gastric) (NN cancer) (NN CD133) (NN induction)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 69:G02.111.087.800|ES| 18:1 19:1 86:1 195:1 207:1 221:1 459:1 651:1 652:1 736:1 843:1 844:1 845:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (JJ biological) (NN function) (NP (NP (JJ related) (JJ molecular) (NN mechanism) (NN PAX5) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 141:G16.100 243:D12.776.260.645.500|ES| 10:1 14:1 19:1 33:1 161:1 162:1 303:1 304:1 324:1 419:1 440:1 441:1 843:1 846:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN apobec-1) (NN gene) (NN expression) (JJ human) (JJ gastrointestinal) (NN tumor) (NN colon) (JJ cancer-derived) (NN cell) (NN line)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 155:G05.355.310 244:C04.588.274.476|ES| 7:1 9:1 19:1 36:1 94:1 113:1 115:1 183:1 264:1 324:1 843:1 847:1 848:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NN rat) (NN model)) (VP (VBG carrying) (NP (JJ knockout) (NN allele) (NN gatekeeper) (NN gene) (NNP Adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN Apc) (-RRB- -RRB-)))) (VP (VBZ recapitulates) (NP (NP (JJ familial) (NN colon) (NN cancer)) (JJ human) (S (ADVP (RB closely)) (VP (VBG existing) (NP (JJ murine) (NN model)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 77:G05.360.340.024.340.030 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 247:G01.374.676.530 248:E05.393.335.750|ES| 9:1 10:1 14:1 18:1 19:1 36:1 58:1 59:1 71:1 72:1 113:1 221:1 230:1 280:1 403:1 627:1 843:1 849:1 850:1 851:1 852:1 853:1 854:1 855:1 856:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN microRNA) (NN miR-221) (NN miR-222)) (VP (VBP regulate) (NP (NP (NP (NN NF-kappaB) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN activation) (JJ human) (NN CRC) (NN cell) (NN line)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 184:D13.150.650.319 210:D12.776.260.600 249:G05.355.315.800 250:E07.305.812|ES| 10:1 14:1 19:1 36:1 94:1 140:1 141:1 221:1 225:1 245:1 251:1 264:1 403:1 487:1 714:1 843:1 857:1 858:1 859:1 860:1 861:1 862:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD wanted) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ genetic) (NN defect) (JJ relevant) (JJ colorectal) (NN cancer)) (, ,) (NP (NN Msh2) (NN p53) (NN deficiency)) (, ,)) (VP (MD would) (VP (VB influence) (NP (NN efficiency) (NN sulindac) (NN chemoprevention) (NN increase) (NN side) (NN effect))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 87:C18.654.521 251:D02.455.426.559.847.486.875 252:F02.784.692.351 253:E02.319.162 254:C16.131|ES| 2:1 12:1 17:1 18:1 19:1 40:1 74:1 75:1 221:1 253:1 585:1 588:1 843:1 863:1 864:1 865:1 866:1 867:1 868:1 869:1 870:1 871:1
-1 	|BT| (S (NP (NP (NP (NN Western) (NN blot) (JJ quantitative) (JJ real-time) (NN PCR)) (PRN (-LRB- -LRB-) (NP (NN qRT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NN MAP4K4) (NN expression)) (VP (ADVP (RB inversely)) (VBD correlated) (NP (NN miR-141) (NN expression) (JJ pancreatic) (NN cancer) (NN sample) (NN cell) (NN line))))))) |ET| |BS|94:A11.251.210 255:E05.196.401.143 256:E05.196.401.143 257:E05.393.620.500.706|ES| 10:1 14:1 18:1 19:1 94:1 115:1 264:1 275:1 418:1 446:1 463:1 465:1 467:1 661:1 817:1 835:1 872:1 873:1 874:1 875:1 876:1
-1 	|BT| (S (NP (NN Western) (NN blot)) (VP (VBD revealed) (NP (NP (NN overexpression) (NN beta-catenin)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (NP (NN cyclooxygenase-2) (NN colon) (NN tumor) (NN sample)))))) |ET| |BS|22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 51:C04.588.274.476.411.307.180 215:D12.644.360.262.150.100 255:E05.196.401.143|ES| 2:1 7:1 19:1 60:1 61:1 63:1 64:1 65:1 66:1 113:1 152:1 275:1 743:1 744:1 824:1 835:1 872:1 873:1
-1 	|BT| (S (NP (NN Wnt/beta-catenin) (NN signaling) (JJ critical) (JJ intestinal) (NN cell) (NN proliferation)) (, ,) (VP (VBD decreased) (NP (NN CDX2) (NN expression) (NN influence) (NN Wnt) (JJ signaling-related) (NN gene) (NN progression) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 16:C23.550.291.656 47:A03.556.124 69:G02.111.087.800 105:G02.149.115.800.925 183:G04.299.233.750|ES| 2:1 9:1 17:1 18:1 19:1 48:1 94:1 109:1 114:1 115:1 195:1 202:1 299:1 302:1 825:1 867:1 877:1 878:1
-1 	|BT| (S (NP (NN YY1)) (VP (VBZ promotes) (NP (NP (NN colon) (NN cancer) (NN growth)) (VP (VBG inhibiting) (NP (NP (NN p53)) (S (VP (VBG promoting) (NP (NN Wnt) (NN signaling) (NN pathway) (NN serf) (JJ independent) (JJ prognostic) (NN biomarker) (NN CRC) (NN patient))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 45:G07.700.320.249 50:M01.643 122:C14.280.383 147:G02.149.115.800.925 158:D23.101 258:D12.776.260.235.875|ES| 12:1 18:1 19:1 102:1 113:1 120:1 195:1 245:1 298:1 383:1 877:1 879:1 880:1 881:1 882:1 883:1 884:1 885:1
1 	|BT| (S (NP (NN SMO)) (VP (MD might) (NP (NP (JJ good) (JJ therapeutic) (NN target) (NN patient)) (NP (JJ colorectal) (NN polyp) (NN carcinoma))) (, ,) (NP (RB even) (NN absence) (NN Hh) (NN signal) (NN activation)))) |ET| |BS|50:M01.643 52:E02 265:C04.557.470.200 444:C23.300.825|ES| 2:1 17:1 19:1 120:1 160:1 225:1 304:1 541:1 647:1 798:1 859:1 1268:1 1270:1 1318:1 1533:1 1534:1
1 	|BT| (S (NP (NN SPOCK1) (NN act) (NN oncogene)) (VP (MD may) (NP (NP (JJ prognostic) (NN factor) (JJ therapeutic) (NN target) (NN patient)) (NP (NNP GBC))))) |ET| |BS|9:G05.360.340.024.340.375.500 50:M01.643 52:E02 81:E02.095.465.425.400.330.050.400|ES| 19:1 24:1 120:1 160:1 185:1 246:1 491:1 541:1 884:1 1535:1 1536:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN downregulation)) (VP (MD might) (VP (VBN involved) (SBAR (S (NP (NP (NN carcinogenesis)) (, ,) (NP (NN growth)) (, ,) (NP (NN invasion) (NN lung) (NN cancer))) (VP (MD could) (VP (VBN considered) (S (NP (JJ promising) (NN marker) (NN gauge) (NN aggressiveness) (NN lung) (NN cancer))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 45:G07.700.320.249 85:G02.111.087.225 158:D23.101 162:F01.145.126.125|ES| 2:1 18:1 19:1 102:1 207:1 328:1 534:1 595:1 620:1 774:1 793:1 798:1 908:1 925:1 1061:1 1316:1 1517:1 1537:1 1538:1 1539:1 1540:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBG finding) (SBAR (S (NP (JJ indicated) (NN PVT1/EZH2/LATS2) (NN interaction)) (VP (MD might) (VP (VB serve) (NP (JJ new) (NN target) (NN lung) (NN adenocarcinoma) (NN diagnosis) (NN therapy)))))))) |ET| |BS|52:E02 263:E01|ES| 2:1 19:1 130:1 160:1 255:1 328:1 532:1 618:1 712:1 798:1 927:1 1037:1 1537:1 1538:1 1541:1 1542:1
1 	|BT| (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (JJ first) (NN time) (NN miR-372)) (VP (VBZ suppresses) (NP (NN tumorigenesis) (NN development) (NN EC))))))) (: ;) (FRAG (NP (NP (NN RhoC)) (JJ new) (ADJP (RB potentially) (JJ important)) (JJ therapeutic) (NN target)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 52:E02 322:G01.910|ES| 2:1 19:1 35:1 78:1 101:1 160:1 217:1 541:1 686:1 712:1 773:1 816:1 902:1 1081:1 1175:1 1537:1 1538:1 1543:1 1544:1 1545:1
1 	|BT| (S (NP (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (JJ present) (NN work)) (VP (VBD revealed) (NP (JJ novel) (NN function) (NN TIP30)) (, ,) (VP (ADVP (RB possibly)) (VBN used) (S (NP (JJ independent) (ADJP (JJ prognostic) (NN factor) (JJ potential)) (JJ therapeutic) (NN target) (JJ gastric) (NN cancer)))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 445:I03.946|ES| 2:1 18:1 19:1 33:1 86:1 160:1 185:1 275:1 476:1 541:1 827:1 883:1 884:1 891:1 1307:1 1537:1 1538:1 1546:1 1547:1 1548:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN SRC-3)) (VP (MD may) (NP (JJ important) (NN oncogene) (JJ therapeutic) (NN target) (NN lung) (NN cancer))))))) |ET| |BS|9:G05.360.340.024.340.375.500 52:E02|ES| 2:1 18:1 19:1 24:1 160:1 328:1 491:1 541:1 793:1 796:1 902:1 1537:1 1538:1 1549:1
1 	|BT| (S (NP (NNP TaqMan) (NN PCR) (NN genotyping) (NN technology)) (VP (VBD used) (VP (VB detect) (NP (NP (NP (NN genotype) (NN ITGA3) (NN gene) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN rs2230392)) (, ,) (NP (NN rs2285524) (NN rs16948627))) (-RRB- -RRB-))) (NP (JJ peripheral) (NN blood)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 61:E05.318.740.600.800 225:E05.337 386:F02.463.425.069 396:G05.380 434:E05.318.308.985.525.375 446:G05.365.795.598 447:C04.557.450.565.575.650 448:E05.393.620.500 449:A12.207.152 450:J01.897|ES| 2:1 7:1 9:1 10:1 14:1 19:1 171:1 336:1 476:1 780:1 875:1 1298:1 1329:1 1476:1 1511:1 1550:1 1551:1 1552:1 1553:1 1554:1 1555:1 1556:1 1557:1 1558:1 1559:1 1560:1 1561:1 1562:1
1 	|BT| (S (NP (JJ Testis-specific) (NN Fank1) (NN gene) (JJ knockdown) (NN mouse)) (VP (VBP produce) (NP (NN oligospermia)) (PP (IN via) (NP (NN apoptosis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 400:E05.393.335.500 451:C12.294.365.700.508 452:A05.360.444.849|ES| 9:1 19:1 52:1 89:1 464:1 596:1 1563:1 1564:1 1565:1 1566:1
1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBD determine) (SBAR (IN whether) (S (S (VP (VBG combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam)))) (VP (MD could) (VP (VB offer) (NP (ADJP (ADJP (JJR better)) (ADJP (JJ therapeutic))) (NN effect) (NN combat) (NN HCC) (NN mouse)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 74:1 75:1 130:1 131:1 221:1 441:1 541:1 691:1 904:1 908:1 1042:1 1088:1 1089:1 1498:1 1567:1 1568:1
1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP evaluate) (NP (NN hypermethylation) (JJ spastic) (NN paraplegia-20) (NN promoter) (JJ potential) (NN biomarker) (JJ prognostic) (NN factor) (JJ gastric) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 158:D23.101 225:E05.337 453:C10.597.622.669|ES| 18:1 19:1 83:1 86:1 131:1 185:1 664:1 691:1 827:1 884:1 885:1 890:1 1567:1 1569:1 1570:1
1 	|BT| (S (S (NP (DT The) (NN aim) (NN work)) (VP (VP (VB evaluate) (SBAR (IN whether) (S (NP (NN TP53) (NN mutation)) (VP (VBN classified) (ADVP (RB functionally)) (ADJP (JJ inactive)))))) (PRN (-LRB- -LRB-) (NP (ADJP (ADJP (JJR <)) (CC or) (ADJP (JJ =))) (ADJP (CD 20) (NN %)) (JJ wildtype) (NN transactivation) (NN ability)) (-RRB- -RRB-))) (S (NP (NP (JJ different) (JJ prognostic) (JJ predictive) (NN value) (NN CRC)) (VBN compared) (NN mutation)) (VP (VBD retained) (NP (JJ significant) (NN activity)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 385:F02.784.629.131 395:L01.100 445:I03.946 454:G05.355.315.800|ES| 10:1 14:1 19:1 34:1 50:1 135:1 221:1 245:1 312:1 369:1 399:1 414:1 533:1 691:1 884:1 890:1 1018:1 1248:1 1300:1 1546:1 1567:1 1571:1 1572:1 1573:1 1574:1 1575:1 1576:1 1577:1
1 	|BT| (NP (NP (NP (DT The) (NN expression) (JJ gastric) (NN cancer) (NN marker) (NN MUC1)) (, ,) (NP (NN MUC2)) (, ,) (NP (NN MUC5AC)) (, ,) (NP (NN oncogene) (NN c-myc)) (, ,) (NP (NN c-met)) (, ,) (NP (NN cyclin) (NN E1)) (, ,) (NP (NN cancer) (NN stem) (NN cell) (NN marker) (NN CD44)) (VP (VBD determined) (NP (NN MGCC3I) (NN cell))))) |ET| |BS|41:A11 158:D23.101 332:A11.872.650|ES| 2:1 18:1 19:1 24:1 86:1 94:1 115:1 210:1 212:1 455:1 534:1 691:1 743:1 1106:1 1578:1 1579:1 1580:1 1581:1 1582:1 1583:1
1 	|BT| (S (NP (NP (DT The) (NN lung) (NN adenocarcinoma) (NN cell) (NN bearing) (JJ K-ras) (NN gene) (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN A549) (NN H820)) (-RRB- -RRB-))) (VP (VBD showed) (NP (ADJP (RB consistently) (JJR higher)) (NN level) (NN cell) (NN motility)) (S (PP (IN without) (NP (NP (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN TKB6) (NN TKB14)) (-RRB- -RRB-)))) (, ,) (NP (NN motility) (NN A549) (NN H820) (NN cell)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN dnAkt) (NN transfection)))))) |ET| |BS|18:G05.365.590 41:A11 122:C14.280.383 217:E05.393.350.810 455:B01.050.150.900.649.147.890|ES| 2:1 9:1 10:1 14:1 19:1 34:1 94:1 124:1 132:1 170:1 249:1 255:1 328:1 364:1 365:1 691:1 746:1 1121:1 1177:1 1195:1 1584:1 1585:1 1586:1 1587:1 1588:1 1589:1
1 	|BT| (FRAG (NP (DT The) (NN morphology) (CD eight) (NN ASPL-TFE3) (JJ fusion-positive) (JJ renal) (NN tumor)) (, ,) (PP (IN although) (NP (NP (VBG overlapping) (NN aspect) (JJ classic) (NNS ASPS)) (, ,) (VP (ADVP (RB closely)) (VBZ resembles) (NP (NP (JJ renal) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN RCC)) (-RRB- -RRB-)))) (, ,) (NP (FW priori) (NN diagnosis) (NN case))))) |ET| |BS|263:E01 274:C04.588.945.947.535 295:C04.557.470.200.025.390|ES| 2:1 7:1 10:1 14:1 19:1 94:1 112:1 304:1 348:1 691:1 855:1 922:1 923:1 934:1 935:1 1037:1 1413:1 1590:1 1591:1 1592:1 1593:1 1594:1 1595:1 1596:1
1 	|BT| (NP (NP (NP (DT The) (JJ recombinant) (NN plasmid)) (NP (VBN transfected) (JJ human) (ADJP (NN lung) (NN cancer) (NN A549) (NN cell) (JJ liposome-mediated)) (NN method)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 456:D25.479.517 457:G05.360.600|ES| 18:1 19:1 36:1 94:1 328:1 364:1 479:1 691:1 1420:1 1597:1 1598:1 1599:1
1 	|BT| (S (NP (DT The) (JJ resultant) (NN MLL) (NN fusion) (NN protein)) (VP (VBN known) (VP (VBP mediate) (NP (NN leukaemia) (NN disruption) (JJ normal) (JJ epigenetic) (NN regulation) (NN target) (NN gene) (NN locus))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 142:I01.880.604 361:C04.557.337 458:G05.360.340.024.380|ES| 4:1 9:1 19:1 118:1 160:1 377:1 438:1 556:1 691:1 936:1 1207:1 1263:1 1600:1 1601:1 1602:1 1603:1
1 	|BT| (S (NP (NP (DT The) (JJ significant) (NN association) (NN SNIP1) (NN c-Myc) (NN staining) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN tissue) (NN array) (NN evidence) (NN activity)) (VP (MD might) (VP (VBN linked)))) (VP (VBZ suggests) (SBAR (S (NP (NN SNIP1)) (VP (MD might) (NP (JJ important) (NN modulator) (NN c-Myc) (NN activity) (NN carcinogenesis))))))) |ET| |BS|12:Z01.542.049 33:C04.697.098 98:A10 110:C04.588.894.797.520.109.220.249 386:F02.463.425.069|ES| 18:1 19:1 38:1 94:1 135:1 207:1 272:1 328:1 331:1 399:1 691:1 694:1 798:1 824:1 902:1 1298:1 1363:1 1604:1 1605:1 1606:1 1607:1
1 	|BT| (S (NP (DT The) (JJ significant) (NN link) (NN tobacco) (NN loss) (NN p16) (NN locus)) (VP (VBZ identifies) (NP (JJ additional) (JJ genetic) (NN target) (NN smoking) (NN pathogenesis) (NN lung) (NN cancer)))) |ET| |BS|203:G05.360.340.024.340.375.249.375 459:B01.650.940.800.575.100.905.900 460:B01.650.940.800.575.100.905.900 461:F01.145.958.500 462:J01.637.836|ES| 18:1 19:1 32:1 135:1 160:1 328:1 377:1 501:1 691:1 864:1 980:1 1313:1 1608:1 1609:1 1610:1 1611:1
1 	|BT| (S (NP (DT The) (JJ siRNA-mediated) (NN DEPDC1) (NN depletion)) (VP (VBD resulted) (NP (NP (JJ significant) (NN inhibition) (NN proliferation) (NN delay) (NN cell) (NN cycle) (NN progression) (NN NPC) (NN cell) (NN line)) (, ,) (NP (NN CNE-1) (NN HNE-1))))) |ET| |BS|16:C23.550.291.656 43:F01.145.544 117:D13.150.650.700 353:G04.299.134|ES| 2:1 19:1 48:1 94:1 103:1 135:1 136:1 264:1 299:1 594:1 601:1 691:1 1174:1 1612:1 1613:1 1614:1 1615:1 1616:1
1 	|BT| (NP (NP (DT The) (JJ unbalanced) (NN translocation)) (, ,) (NP (NN der) (-LRB- -LRB-) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;) (CD q25)) (-RRB- -RRB-) (, ,) (NP (NP (JJ characteristic) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (PRN (-LRB- -LRB-) (NP (NN ASPS)) (-RRB- -RRB-)))) |ET| |BS|439:C04.557.450.590.775 463:C23.550.210.870|ES| 2:1 10:1 14:1 19:1 217:1 336:1 451:1 691:1 923:1 929:1 930:1 931:1 932:1 1117:1 1287:1 1524:1 1617:1 1618:1 1619:1
1 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1
1 	|BT| (S (NP (DT These) (NNS data) (NN challenge) (NN view) (NN MYH11) (NN passive) (NN differentiation) (NN marker)) (VP (VBG functioning) (S (NP (NN muscle) (NN contraction)) (VP (VBP add) (S (VP (VBG understanding) (NP (JJ intestinal) (NN neoplasia)))))))) |ET| |BS|74:G04.299.151 102:C04.588.274.476.411 158:D23.101 239:F02.463.188.357 375:Z01.639.100 464:G11.427.590.540|ES| 19:1 109:1 215:1 534:1 640:1 792:1 793:1 905:1 1371:1 1626:1 1627:1 1628:1 1629:1 1630:1 1631:1 1632:1
1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP indicate) (SBAR (S (NP (NNP BIM) (NN deletion) (NN polymorphism) (JJ common) (JJ Korean) (NN NSCLC) (NN patient)) (ADVP (RB significantly)) (VP (VBP affect) (NP (JJ intrinsic) (JJ biologic) (NN function) (JJ BH3-only) (NN protein)))))))) |ET| |BS|7:D12.776 50:M01.643 110:C04.588.894.797.520.109.220.249 306:G05.355.600.800 307:G05.365.795 433:F01.470.047 465:D23|ES| 4:1 19:1 33:1 120:1 124:1 329:1 655:1 792:1 927:1 1059:1 1060:1 1479:1 1486:1 1633:1 1634:1 1635:1 1636:1 1637:1
1 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1
1 	|BT| (NP (NP (DT These) (UCP (S (VP (VBG finding) (PP (VBN suggested) (NP (NN endostatin) (NN gene) (NN therapy))) (, ,) (S (VP (VBG using) (NP (JJ cationic) (JJ vector-mediated) (JJ intravenous) (NN gene) (NN transfer)))))) (, ,) (MD might) (NP (NP (JJ feasible) (NN strategy) (JJ organ-targeted) (NN prevention) (NN regulation)) (JJ possible) (VBN disseminated) (NN cancer))))) |ET| |BS|123:G05.360.337 142:I01.880.604 466:D12.644.276.100.450.750 467:D01.248.497.300|ES| 2:1 9:1 18:1 19:1 130:1 350:1 438:1 792:1 798:1 925:1 927:1 1114:1 1359:1 1474:1 1640:1 1641:1 1642:1 1643:1 1644:1 1645:1 1646:1 1647:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (NP (NP (NN favour) (ADJP (ADJP (JJ non-invasive)) (, ,) (ADJP (JJ ALK-gene))) (NN status)) (JJ pre-screening) (JJ routine) (NN basis) (NNS CTCs)) (VP (VBN isolated) (NP (NP (NN patient) (NN lung) (NN cancer)) (SBAR (S (NP (JJ open) (JJ new) (NN avenue) (JJ real-time) (NN monitoring)) (VP (VBD adapted) (NP (VBN targeted) (NN therapy)))))))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 52:E02 322:G01.910 468:G07.700.062.133|ES| 2:1 16:1 18:1 19:1 101:1 120:1 130:1 328:1 416:1 712:1 792:1 874:1 1140:1 1361:1 1648:1 1649:1 1650:1 1651:1 1652:1 1653:1 1654:1 1655:1 1656:1 1657:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP implicate) (S (NP (NN SPARC) (NN promoter) (NN methylation) (JJ important) (NN factor) (NN tumorigenesis) (JJ gastric) (NN carcinoma)) (VP (VB provide) (NP (NP (JJ new) (NN insight) (JJ potential) (NN use)) (NP (NNP SPARC) (JJ novel) (NN biomarker) (JJ potential) (JJ clinical) (NN importance) (JJ human) (JJ gastric) (NN cancer)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 36:G02.111.087.029.538 37:D12.776.157.125.715 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875 158:D23.101 259:D12.776.395.240.150.500 265:C04.557.470.200|ES| 18:1 19:1 36:1 78:1 81:1 82:1 83:1 84:1 86:1 101:1 185:1 304:1 711:1 712:1 792:1 827:1 885:1 891:1 902:1 1141:1 1658:1 1659:1 1660:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NP (JJ VES-induced) (NN expression) (NN NAG-1) (NN mRNA/protein)) (VP (VBN regulated) (NP (JJ transcriptional/post-transcriptional) (NN mechanism) (NN p38) (JJ kinase-dependent) (NN manner) (NN NAG-1) (JJ chemopreventive/therapeutic) (NN target) (NN prostate) (NN cancer)))))))) |ET| |BS|7:D12.776 52:E02 111:D13.444.735.544 142:I01.880.604 209:G02.111.087.847 469:D08.811.913.696 470:C02.782.160.927|ES| 18:1 19:1 77:1 101:1 115:1 160:1 162:1 792:1 1479:1 1661:1 1662:1 1663:1 1664:1 1665:1 1666:1 1667:1 1668:1 1669:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP reveal) (NP (NN association) (NN SNP) (NN rs7646) (NN NTD) (NN risk))) (VP (VBZ involves) (NP (NP (NN difference) (NN microRNA) (NN regulation)) (, ,) (NP (NN highlight) (NN importance) (JJ genotype-dependent) (JJ differential) (NN microRNA) (NN regulation) (NN relation) (JJ human) (NN disease) (NN risk)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 61:E05.318.740.600.800 142:I01.880.604 184:D13.150.650.319 288:C23.550.288 386:F02.463.425.069 396:G05.380 411:C10.500.680 446:G05.365.795.598|ES| 2:1 19:1 36:1 101:1 171:1 438:1 792:1 857:1 998:1 1298:1 1561:1 1660:1 1670:1 1671:1 1672:1 1673:1 1674:1 1675:1 1676:1 1677:1 1678:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (NN ERBB4) (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN target) (NN subset) (NN CRC))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 259:D12.776.395.240.150.500|ES| 19:1 101:1 160:1 245:1 541:1 792:1 796:1 891:1 1285:1 1679:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (NP (NN IFN-alpha) (NN gene) (NN therapy) (JJ promising) (NN strategy) (NN treat) (NNP HCC) (NN patient)) (JJ concomitant) (NN liver) (NN cirrhosis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 104:C04.557.470.200.025.255 357:C06.552.630|ES| 9:1 19:1 101:1 120:1 130:1 441:1 792:1 796:1 836:1 1090:1 1114:1 1199:1 1517:1 1680:1 1681:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (VBN suggested) (NN PSMA6) (NN serf) (JJ attractive) (NN target) (JJ high) (JJ therapeutic) (NN index) (NN lung) (NN cancer)))) |ET| |BS|52:E02|ES| 18:1 19:1 101:1 160:1 178:1 328:1 541:1 721:1 792:1 882:1 925:1 1242:1 1682:1
1 	|BT| (S (NP (NP (DT This) (NN study)) (VP (VBN designed))) (VP (VBP identify) (SBAR (S (NP (JJ TLR4-mediated) (NN gene) (NN expression) (NN pathway)) (VP (MD may) (VP (VBN used) (SBAR (S (NP (JJ prognostic) (NP (NN indicator) (NN susceptibility) (NN lung) (NN tumorigenesis) (NN mouse))) (VP (VBP provide) (NP (NN insight) (NN mechanism))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 155:G05.355.310 182:A04.411 401:C23.550.291.687 471:D27.720.470.410|ES| 9:1 19:1 52:1 78:1 115:1 131:1 162:1 328:1 383:1 476:1 491:1 711:1 807:1 832:1 884:1 1141:1 1353:1 1683:1 1684:1 1685:1
1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
1 	|BT| (S (NP (DT This)) (VP (VBZ suggests) (SBAR (S (NP (NN c-Jun) (NN inhibition)) (VP (MD may) (VP (VB serve) (NP (JJ therapeutic) (NN target) (NN liver) (NN cancer)))))))) |ET| |BS|43:F01.145.544 52:E02|ES| 18:1 19:1 103:1 160:1 331:1 491:1 532:1 541:1 807:1 836:1 1686:1
1 	|BT| (S (PP (IN Through) (NP (NN combination) (NNS data) (NN mining) (JJ biochemical) (NN assay))) (, ,) (VP (VBD identified) (NP (NP (NN trophinin)) (, ,) (VP (MD could) (VP (VB enhance) (NP (NP (NN cell) (NN invasion)) (, ,) (NP (NP (JJ novel) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer)))))))) |ET| |BS|41:A11 106:E05.091 182:A04.411 259:D12.776.395.240.150.500 472:L01.313.500.750.280.199 473:E01.789.625|ES| 2:1 18:1 19:1 94:1 185:1 310:1 328:1 530:1 620:1 623:1 793:1 884:1 891:1 908:1 1128:1 1129:1 1266:1 1687:1 1688:1 1689:1 1690:1
1 	|BT| (NP (NP (ADVP (RB Thus)) (, ,) (NP (NP (NN inactivation) (NN p16) (NN gene) (JJ common) (NN event) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (, ,) (NP (NN mechanism) (NN gene) (NN alteration)) (VP (VBZ differs) (NP (NN smoker) (NN nonsmoker)))))) |ET| |BS|18:G05.365.590 42:G05.355.315.203.374 110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375|ES| 2:1 9:1 18:1 19:1 94:1 162:1 205:1 328:1 655:1 694:1 951:1 1313:1 1314:1 1315:1 1691:1 1692:1 1693:1
1 	|BT| (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NN DAP) (NN kinase) (NN promoter)) (NN methylation)) (VP (VBZ contributes) (NP (NP (NN TRAIL) (NN resistance) (NN NSCLC) (NN cell)) (, ,) (NP (NP (VBN measured) (NN DAP) (NN kinase) (NN promoter) (NN methylation) (NN gene) (NN expression) (NN status)) (NP (CD 11) (NN NSCLC) (NN cell) (NN line)))))))))) (VP (VBD correlated) (NP (NN methylation/expression) (NN status) (NN sensitivity) (NN cell) (NN TRAIL)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 94:A11.251.210 110:C04.588.894.797.520.109.220.249 155:G05.355.310 228:E05.978 474:D08.811.913.696.620.682.700.125.387|ES| 2:1 9:1 19:1 74:1 81:1 83:1 94:1 115:1 221:1 264:1 329:1 416:1 446:1 470:1 607:1 789:1 828:1 845:1 1057:1 1094:1 1694:1 1695:1 1696:1
1 	|BT| (S (S (VP (TO To) (VP (VB elucidate) (NP (JJ pathogenic) (NN role) (NN MLL) (NN fusion) (NN protein) (NN HOX) (NN dysregulation) (NN leukaemia))))) (, ,) (VP (VBD generated) (NP (JJ novel) (JJ haematopoietic) (JJ lineage-specific) (NN Mll-Een) (NN knock-in) (NN mouse) (NN model)) (S (VP (VBG using) (NP (JJ Cre-mediated) (NN inversion) (NN strategy)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 259:D12.776.395.240.150.500 327:G06.930 361:C04.557.337 475:C23.550.210.190 476:A15.378|ES| 2:1 4:1 19:1 31:1 52:1 72:1 73:1 350:1 828:1 891:1 936:1 1114:1 1202:1 1204:1 1207:1 1263:1 1697:1 1698:1 1699:1 1700:1 1701:1 1702:1 1703:1 1704:1
1 	|BT| (SINV (S (VP (TO To) (VP (VB determine) (NP (NP (JJ genetic) (JJ molecular) (JJ characteristic) (NN tumor)) (VP (VBG carrying) (NP (NN EGFR) (NN gene) (NN mutation))))))) (, ,) (VBD investigated) (S (S (NP (NN EGFR) (NN gene) (NN status) (NN lung) (NN adenocarcinoma)) (VP (VBD evaluated) (NP (NN association) (JJ specific) (JJ characteristic) (NN patient) (NN tumor)))) (, ,) (NP (NP (NP (NP (NX (NN mutation) (NNP KRAS) (NN p53)) (, ,) (NN EGFR) (NN ErbB2) (NN gene) (NN amplification)) (, ,) (NP (NN level) (NN EGFR) (NN HER2) (NN protein)) (, ,)) (NN level) (JJ downstream) (NN effector) (NN EGFR)) (, ,) (NP (JJ phospho-extracellular) (JJ signal-regulated) (NN kinase) (NN phospho-S6) (NN protein))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 8:C04 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337 247:G01.374.676.530 358:G05.360.340.024.340.375.500.791.295.300 386:F02.463.425.069 388:G05.360.340.024.340.375.500.791.550 392:G05.355.315.250 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567|ES| 2:1 4:1 7:1 9:1 12:1 19:1 34:1 74:1 120:1 161:1 187:1 188:1 249:1 255:1 328:1 336:1 403:1 416:1 470:1 540:1 560:1 570:1 780:1 828:1 850:1 864:1 921:1 1298:1 1305:1 1705:1 1706:1 1707:1 1708:1
1 	|BT| (S (NP (PP (TO To) (NP (NN knowledge))) (, ,) (JJ first) (NN study) (NN report) (NN change) (NN lncRNA) (NN expression) (NN profile)) (VP (VBD induced) (NP (NN resveratrol) (NN lung) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 479:G08.686.157.500 480:D13.444.735.790.375 481:D13.444.735.790.375 482:K01.468|ES| 2:1 18:1 19:1 115:1 131:1 200:1 328:1 412:1 417:1 816:1 828:1 1709:1 1710:1 1711:1 1712:1
1 	|BT| (NP (NP (JJ Tubular) (NN atrophy) (JJ low) (NN netrin-1) (NN gene) (NN expression)) (NP (VBN associated) (VBN delayed) (NN kidney) (NN allograft) (NN function))) |ET| |BS|155:G05.355.310 483:C23.300.070 484:A01.941.500 485:A05.810.453 486:E04.936.864|ES| 9:1 19:1 33:1 115:1 169:1 531:1 1713:1 1714:1 1715:1 1716:1 1717:1 1718:1
1 	|BT| (S (S (VP (VBG Using) (NP (NP (JJ Mll-Een-expressing) (JJ leukaemic) (NN cell) (NN line)) (VP (VBN derived) (S (NP (NP (NN bone) (NN marrow) (NN Mll) (-LRB- -LRB-) (NN Een) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (: /) (CC +) (-RRB- -RRB-))) (VP (JJ mutant) (NP (NN mouse)))))))) (, ,) (VP (VBD showed) (NP (NP (NN induction) (NN Hox) (NN gene) (JJ leukaemic) (NN cell)) (VP (VBN associated) (NP (NP (JJ hypomethylated) (NN promoter) (NN region)) (NP (JJ aberrant) (JJ active) (NN chromatin) (NN state) (NN Hox) (NN locus))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 41:A11 94:A11.251.210 196:G02.111.570.080.689.675 397:A11.284.430.106.279.345.190.160.180 487:G05.355.315.800 488:A15.382.216|ES| 2:1 9:1 10:1 14:1 19:1 52:1 83:1 94:1 132:1 169:1 197:1 264:1 377:1 526:1 667:1 736:1 811:1 1203:1 1286:1 1346:1 1347:1 1348:1 1719:1 1720:1 1721:1 1722:1 1723:1 1724:1 1725:1 1726:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBP demonstrate) (SBAR (S (NP (NN dysregulation) (NN HAO2) (JJ early) (NN event) (NN development) (NN HCC)) (VP (MD may) (VP (VB represent) (NP (ADJP (ADJP (JJ useful)) (ADJP (JJ diagnostic))) (JJ prognostic) (NN marker) (JJ human) (NN HCC)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 158:D23.101 263:E01|ES| 5:1 19:1 35:1 36:1 205:1 441:1 491:1 502:1 534:1 799:1 843:1 884:1 903:1 1036:1 1128:1 1202:1 1727:1
1 	|BT| (S (NP (PRP We)) (VP (VBD confirmed) (NP (NP (JJ allelic) (NN loss) (NNS metaplasias)) (NP (JJ bronchiolar) (NN epithelium) (NN IPF) (NN FISH) (NN analysis) (NN FHIT) (NN gene))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 48:C23.550.589 62:A10.272 260:E01.370.225.562 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500 489:B01.050.150.900.493|ES| 9:1 19:1 32:1 173:1 661:1 843:1 938:1 946:1 1122:1 1222:1 1223:1 1475:1 1728:1
1 	|BT| (S (NP (PRP We)) (VP (VBD confirmed) (S (NP (JJ balanced) (NN nature)) (-LRB- -LRB-) (NP (NP (NP (NP (NN X) (: ;) (CD 17) (-RRB- -RRB-) (NN translocation) (NN fluorescence) (FW situ) (NN hybridization)) (NP (CD seven) (JJ renal) (NN tumor)) (ADVP (RB thus)) (VP (VBN analyzed))) (, ,) (NP (NP (NN contrast)) (ADJP (RB sharply) (JJ unbalanced)) (NN nature) (NN translocation) (NNS ASPS))))))) |ET| |BS|274:C04.588.945.947.535 463:C23.550.210.870 490:E01.370.225.500.620.670.325.350 491:D27.505.259.500 492:K01.637|ES| 2:1 7:1 10:1 14:1 19:1 217:1 843:1 922:1 923:1 928:1 929:1 930:1 938:1 1168:1 1334:1 1392:1 1617:1 1618:1 1729:1 1730:1 1731:1 1732:1 1733:1 1734:1
1 	|BT| (S (NP (PRP We)) (VP (VBP describe) (ADVP (RB herein)) (SBAR (S (NP (NP (CD eight) (RB morphologically) (JJ distinctive) (JJ renal) (NN tumor)) (VP (VBG occurring) (NP (JJ young) (NNS people)))) (VP (VBP bear) (NP (NP (JJ identical) (NN ASPL-TFE3) (NN fusion) (NN transcript) (NN ASPS)) (, ,) (FRAG (NP (NN distinction)) (-LRB- -LRB-) (NP (NP (NN X) (: ;) (CD 17) (-RRB- -RRB-) (NN translocation)) (ADJP (RB cytogenetically) (JJ balanced)) (JJ renal) (NN tumor))))))))) |ET| |BS|274:C04.588.945.947.535 455:B01.050.150.900.649.147.890 463:C23.550.210.870 493:M01|ES| 2:1 7:1 10:1 14:1 19:1 111:1 217:1 843:1 922:1 923:1 928:1 929:1 930:1 935:1 936:1 937:1 1525:1 1590:1 1618:1 1735:1 1736:1 1737:1 1738:1 1739:1 1740:1 1741:1 1742:1 1743:1
1 	|BT| (S (NP (PRP We)) (VP (VBD explored) (NP (NP (JJ potential) (NN TFPI2) (NN biomarker) (JJ early) (NN detection) (NN CRC)) (VP (VBG using) (NP (NP (NN stool) (JJ DNA-based) (NN assay) (NN patient)) (JJ nonmetastatic) (NN CRC) (JJ average-risk) (NN noncancer) (NN control) (NN candidate) (NN screening)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 61:E05.318.740.600.800 106:E05.091 158:D23.101 198:D13.444.308 333:D01.045 355:A12.459 375:Z01.639.100 494:E01.390|ES| 19:1 120:1 245:1 289:1 310:1 350:1 499:1 827:1 843:1 885:1 1023:1 1128:1 1184:1 1185:1 1188:1 1243:1 1744:1 1745:1 1746:1 1747:1
1 	|BT| (S (NP (PRP We)) (VP (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NN kallistatin) (NN gene) (NN therapy)) (VP (VBD suppressed) (NP (NP (NN growth) (NN HCC) (NN tumor) (JJ anti-angiogenic) (NN activity)) (, ,) (NP (NN meloxicam)) (, ,) (NP (JJ selective) (NN COX-2) (NN inhibitor))))))) (, ,) (VP (VBD inhibited) (NP (NN proliferation) (JJ induced) (NN apoptosis) (JJ human) (NN HCC) (NN cell) (NN vitro))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 349:D27.505.519.389.310.500|ES| 2:1 7:1 9:1 19:1 36:1 76:1 89:1 94:1 102:1 130:1 216:1 299:1 307:1 365:1 380:1 399:1 412:1 441:1 843:1 993:1 1088:1 1089:1 1527:1 1748:1 1749:1
1 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (S (NP (NNP BIM) (NN intron) (CD 2) (NN deletion) (NN polymorphism) (NN increase) (NN lung) (NN cancer) (NN risk)) (VP (VBZ predicts) (NP (NP (NP (JJ poor) (NN prognosis) (JJ non-small) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN patient))))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 159:I01.880.735.634 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 10:1 14:1 18:1 19:1 40:1 120:1 148:1 171:1 328:1 329:1 544:1 545:1 694:1 843:1 1058:1 1059:1 1060:1 1633:1 1750:1 1751:1
1 	|BT| (S (NP (PRP We)) (VP (VBD identified) (NP (NP (NP (NP (NP (JJ multiple) (JJ somatic) (NN mutation) (NN CCPRCC) (NN case)) (, ,) (PP (VBG including) (ADJP (JJ recurrent)))) (PRN (-LRB- -LSB-) (NP (NP (CD 3/14) (NN case)) (PRN (-LRB- -LRB-) (NP (CD 21) (NN %)) (-RRB- -RRB-))) (-RRB- -RSB-))) (JJ non-synonymous) (NN T992I) (NN mutation) (NN MET) (NN proto-oncogene)) (, ,) (NP (NP (NN gene)) (VP (VBN associated) (NP (NP (JJ epithelial-to-mesenchymal) (NN transition)) (PRN (-LRB- -LRB-) (NP (NN EMT)) (-RRB- -RRB-)))))))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 235:G05.360.340.024.340.375.500.791 443:G05.700.264 495:G04.299.335.500 496:C23.550.291.937 497:G05.365.590.650|ES| 2:1 9:1 10:1 14:1 19:1 34:1 169:1 369:1 388:1 552:1 561:1 563:1 623:1 649:1 843:1 934:1 957:1 1373:1 1378:1 1752:1 1753:1 1754:1 1755:1 1756:1 1757:1 1758:1 1759:1
1 	|BT| (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ autophagy) (VBN involved) (JJ NAC1-mediated) (NN resistance) (NN cisplatin)) (, ,) (NP (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN drug) (NN treatment) (JJ ovarian) (NN cancer))))) |ET| |BS|52:E02 67:D26 151:E02.319 390:G04.299.139.399 498:D01.210.375|ES| 2:1 15:1 18:1 19:1 191:1 417:1 476:1 546:1 774:1 843:1 1094:1 1317:1 1760:1 1761:1 1762:1 1763:1
1 	|BT| (NP (NP (NP (NP (NN Xeroderma) (NN pigmentosum) (NN variant)) (PRN (-LRB- -LRB-) (NP (NN XP-V)) (-RRB- -RRB-))) (NP (JJ rare) (JJ genetic) (NN disease)) (, ,) (NP (VBN characterized) (NN sunlight) (NN sensitivity) (NN predisposition) (JJ cutaneous) (NN malignancy)))) |ET| |BS|401:C23.550.291.687 499:G01.358.500.505.650.836 500:C23.550.291.906 501:C04.834.867 502:C16.320|ES| 2:1 10:1 14:1 19:1 49:1 607:1 864:1 985:1 990:1 998:1 1322:1 1764:1 1765:1 1766:1 1767:1 1768:1 1769:1
-1 	|BT| (NP (NP (NNP Parkin) (NN tumor) (NN suppressor) (NN gene) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249|ES| 7:1 9:1 19:1 303:1 304:1 700:1 2167:1
-1 	|BT| (S (NP (NP (NNP PIRC) (NN rat)) (PRN (-LRB- -LRB-) (NP (NP (NN F344/NTac-Apc)) (PRN (-LRB- -LRB-) (NP (NN am1137)) (-RRB- -RRB-))) (-RRB- -RRB-))) (NP (VBN mutated) (NN Apc) (NN gene)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (NN colon)) (NP (NN tumor)) (ADVP (RB thus)) (VP (NP (VBG mimicking) (JJ familial) (NP (NP (JJ adenomatous) (NN polyposis) (-LRB- -LRB-) (NN FAP) (-RRB- -RRB-) (JJ sporadic) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (RB closely) (JJ Apc-based) (JJ rodent) (NN model)) (S (VP (VBG developing) (NP (NP (NN tumor)) (ADJP (RB mostly) (JJ small)) (NN intestine))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 21:G05.360.340.024.340.375.249.050 51:C04.588.274.476.411.307.180 102:C04.588.274.476.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 333:D01.045 514:B01.050.150.900.649.865 590:B01.050.050.199.520.760.200|ES| 7:1 9:1 10:1 14:1 17:1 18:1 19:1 57:1 58:1 72:1 113:1 229:1 245:1 280:1 356:1 590:1 648:1 725:1 750:1 849:1 854:1 855:1 1334:1 1506:1 2133:1 2168:1 2169:1 2170:1 2171:1 2172:1 2173:1 2174:1
-1 	|BT| (S (NP (NP (NP (JJ Real-time) (JJ reverse) (NN transcription) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD demonstrated) (NP (NP (NN up-regulation) (JJ oncogenic) (NN miR-155)) (, ,) (NP (NP (NN miR-221)) (: /) (NP (CD 222))) (, ,) (NP (NP (NN miR-21) (NN down-regulation) (JJ abundant) (JJ liver-specific) (NN miR-122)) (JJ early) (NN stage) (NN hepatocarcinogenesis))))) |ET| |BS|85:G02.111.087.225 242:A03.620 249:G05.355.315.800 272:E05.393.620.500.725 279:D27.888.569.100 339:G02.111.087.880 346:E05.393.620.500.706 591:G02.111.087.847.500|ES| 2:1 10:1 14:1 19:1 257:1 394:1 487:1 661:1 768:1 896:1 900:1 939:1 941:1 953:1 1128:1 1129:1 1148:1 1175:1 1789:1 1798:1 1799:1 1911:1 2175:1 2176:1 2177:1
-1 	|BT| (S (ADVP (RB Recently)) (, ,) (S (NP (NP (NN microRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (VP (VBD proved) (NP (NP (NN play) (JJ important) (NN role)) (NP (JJ hepatocellular) (NN carcinoma))))) (, ,) (NP (NP (NN function) (NN context) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN BC)) (-RRB- -RRB-))) (VP (VBP remain) (ADJP (JJ unknown)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 104:C04.557.470.200.025.255 184:D13.150.650.319|ES| 2:1 10:1 14:1 18:1 19:1 23:1 31:1 33:1 238:1 303:1 304:1 902:1 1789:1 1857:1 1999:1 2178:1 2179:1 2180:1 2181:1 2182:1
-1 	|BT| (S (ADVP (RB Recently)) (, ,) (NP (NP (NP (NP (NN microRNA-7)) (PRN (-LRB- -LRB-) (NP (NN miR-7)) (-RRB- -RRB-))) (NP (NP (JJ proven) (NN play) (JJ substantial) (NN role)) (NP (NN glioblastoma) (NN breast) (NN cancer)))) (, ,) (NP (NN function) (NN context) (NNP HCC))) (VP (VBP remain) (ADJP (JJ unknown)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 104:C04.557.470.200.025.255 184:D13.150.650.319 592:C04.557.465.625.600.380.080.335|ES| 2:1 10:1 14:1 18:1 19:1 23:1 31:1 33:1 238:1 441:1 1293:1 1999:1 2178:1 2181:1 2182:1 2183:1 2184:1 2185:1 2186:1
-1 	|BT| (S (NP (NN Role) (NN microRNA-155) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ choline-deficient) (NN amino) (JJ acid-defined) (NN diet) (NN C57BL/6) (NN mouse)))) |ET| |BS|15:F01.829.316.616 184:D13.150.650.319 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 19:1 52:1 412:1 900:1 1128:1 1129:1 1957:1 2187:1 2188:1 2189:1 2190:1 2191:1 2192:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN ATA)) (VP (MD may) (NP (JJ broad) (NN utility) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer))))))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 520:C10.228.140.252.190.530.060|ES| 2:1 18:1 19:1 23:1 491:1 546:1 793:1 796:1 1537:1 1538:1 1820:1 2193:1 2194:1 2195:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NN study) (VP (VBP indicate) (SBAR (S (NP (VBN upregulated) (NN BYSL) (NN expression)) (VP (VBP play) (NP (NN role) (NN hepatocarcinogenesis))))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693|ES| 2:1 19:1 31:1 115:1 125:1 131:1 238:1 900:1 1479:1 1537:1 1538:1 2196:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VB identify) (SBAR (S (NP (NN downregulation) (NN miR-497) (JJ important) (NN mechanism) (NN upregulation) (NN IGF1-R) (NN CRC) (NN cell)) (VP (VBZ contributes) (NP (NN malignancy) (NN CRC)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 249:G05.355.315.800 339:G02.111.087.880 375:Z01.639.100 598:D12.644.276.937.400 599:M01.526.799.500|ES| 2:1 19:1 49:1 94:1 101:1 162:1 245:1 595:1 832:1 845:1 902:1 1126:1 1537:1 1538:1 2197:1 2198:1
-1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
-1 	|BT| (NP (NP (NP (DT The) (NN APC) (NN gene) (NN play) (JJ major) (NN role)) (NP (JJ human) (NN colon) (NN carcinogenesis)))) |ET| |BS|15:F01.829.316.616 21:G05.360.340.024.340.375.249.050 33:C04.697.098 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693|ES| 9:1 11:1 19:1 31:1 36:1 113:1 207:1 238:1 462:1 691:1
-1 	|BT| (NP (NP (NP (DT The) (NN B-cell) (NN tumor) (NN promoter)) (SBAR (S (NP (NN Bcl-3)) (VP (VBZ suppresses) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis) (JJ epithelial) (NN cell))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 53:C06.405.205.265 75:A11.436 310:A11.063.438 600:D27.888.569.100|ES| 7:1 19:1 78:1 83:1 94:1 113:1 127:1 404:1 686:1 691:1 1849:1 2199:1
-1 	|BT| (S (NP (DT The) (NP (NN c-myc) (NN oncogene) (NN play) (JJ important) (NN role)) (NN tumorigenesis)) (ADVP (RB frequently)) (VP (VBD deregulated) (NP (NP (JJ many) (JJ human) (NN cancer)) (, ,) (PP (VBG including) (NP (JJ gastrointestinal) (NN cancer)))))) |ET| |BS|9:G05.360.340.024.340.375.500 12:Z01.542.049 15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693|ES| 2:1 18:1 19:1 24:1 31:1 36:1 78:1 183:1 238:1 455:1 561:1 691:1 698:1 902:1 1040:1 1965:1
-1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
-1 	|BT| (S (NP (DT The) (NN finding) (JJ parkin-deficient) (NN mouse) (JJ susceptible) (NN hepatocarcinogenesis)) (VP (VBN provided) (VP (JJ first) (NP (NN evidence) (VP (VBG showing) (NP (JJ parkin) (ADVP (RB indeed)) (NP (NN tumor) (NN suppressor) (NN gene)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 206:G05.360.340.024.340.375.249 275:C23.888|ES| 7:1 9:1 19:1 38:1 52:1 691:1 700:1 816:1 899:1 900:1 927:1 1155:1 2200:1 2201:1 2202:1 2203:1
-1 	|BT| (S (NP (DT The) (NN finding)) (VP (MD may) (VP (VB provide) (NP (NP (NN basis) (NN understanding) (JJR greater) (NN predisposition) (JJ intestinal) (NN cancer) (NN Mlh1)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 101:C04.588.274.476.411 239:F02.463.188.357 401:C23.550.291.687|ES| 10:1 14:1 18:1 19:1 45:1 52:1 109:1 491:1 586:1 691:1 711:1 905:1 927:1 1140:1 1768:1 2204:1
-1 	|BT| (NP (NP (NP (DT The) (NP (NN ITF-2) (NN gene))) (JJ located) (JJ chromosomal) (NN region) (NN 18q21)) (: ;) (S (NP (JJ allelic) (NN loss) (NN locus)) (VP (VBZ occurs) (NP (ADJP (CD 70) (NN %)) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 6:G05.360.340.024.340 289:A11.284.187 290:G05.365.590.029.530 292:Z01|ES| 9:1 17:1 18:1 19:1 32:1 217:1 369:1 377:1 657:1 667:1 691:1 1002:1 1475:1 2038:1 2040:1 2205:1 2206:1
-1 	|BT| (NP (NP (DT The) (NN K-sam) (NN gene)) (, ,) (VP (ADVP (RB originally)) (VBN isolated) (NP (NP (VBN amplified) (NN gene) (NN stomach) (NN cancer) (NN cell) (NN line) (NN KATO-III)) (, ,) (VP (VBN characterized) (S (NP (NP (NP (JJ preferential) (NN amplification) (JJ undifferentiated) (NN type)) (PRN (-LRB- -LRB-) (NP (JJ diffuse) (NN type)) (-RRB- -RRB-))) (NN stomach) (NN cancer)) (VP (VBZ encodes) (NP (CD one) (NN receptor) (JJ heparin-binding) (NN growth) (NN factor) (NN fibroblast) (NN growth) (NN factor)))))))) |ET| |BS|6:G05.360.340.024.340 94:A11.251.210 232:D02.886.030.676.180 601:D12.644.276.624 602:D09.698.373.400|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 102:1 185:1 186:1 264:1 543:1 653:1 691:1 801:1 803:1 804:1 921:1 985:1 1010:1 1653:1 2207:1 2208:1 2209:1 2210:1 2211:1 2212:1 2213:1
-1 	|BT| (UCP (S (NP (DT The) (NN miR-122) (JJ regulatory) (NN circuitry) (NN implication) (NN hepatocarcinogenesis)) (VP (VBN identified) (S (VP (VBG using) (NP (NN liver) (JJ different) (NN development) (NN stage)))))) (, ,) (NP (NP (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NN tissue) (NN cell) (NN line)) (, ,) (NP (NP (NN aflatoxin) (NN B)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (-LRB- -LRB-) (NN AFB) (LST (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (-RRB- -RRB-)))) (: -) (NP (VBN transformed) (NN cell)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 98:A10 104:C04.557.470.200.025.255 242:A03.620 603:D03.383.663.283.119.075|ES| 2:1 10:1 14:1 19:1 35:1 36:1 85:1 94:1 98:1 264:1 272:1 303:1 304:1 350:1 414:1 441:1 623:1 691:1 763:1 836:1 900:1 1129:1 1789:1 1817:1 1818:1 2214:1 2215:1 2216:1
-1 	|BT| (S (NP (DT The) (NN orphan) (NN cotransport) (NN protein)) (VP (VBD expressed) (NP (NP (NP (NN SLC5A8) (NN gene) (VBN shown) (NN play) (NN role)) (NP (VBG controlling) (NN growth) (NN colon) (NN cancer))) (, ,) (NP (NN silencing) (NP (NN gene) (JJ common) (NP (JJ early) (NN event) (JJ human) (NN colon) (NN neoplasia))))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 42:G05.355.315.203.374 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 604:M01.108|ES| 2:1 4:1 6:1 9:1 18:1 19:1 31:1 36:1 100:1 102:1 113:1 205:1 237:1 238:1 640:1 655:1 691:1 1128:1 2217:1 2218:1 2219:1 2220:1
-1 	|BT| (NP (NP (NP (DT The) (JJ potential) (NN utility) (NN acetyltanshinone) (NN IIA) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer)) (: :) (NP (NP (NN Induction) (NN cancer) (NN cell) (NN death)) (VP (VBG targeting) (NP (JJ apoptotic) (JJ metabolic) (NN signaling) (NN pathway)))))) |ET| |BS|33:C04.697.098 39:G04.299.139.160 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 126:G02.111.087.800 134:G04.299.139 605:G03.495.553|ES| 18:1 19:1 23:1 94:1 104:1 195:1 383:1 411:1 546:1 616:1 691:1 827:1 2006:1 2020:1 2194:1 2195:1 2221:1 2222:1 2223:1
-1 	|BT| (S (NP (NP (DT The) (NN proliferation)) (NP (JJ certain) (NP (JJ human) (JJ HER2-positive) (NN breast) (NN cancer) (NN line)))) (ADVP (RB also)) (VP (VBZ requires) (SBAR (S (NP (NP (NN HSF1)) (, ,) (NP (NN knockdown))) (VP (VBD led) (NP (NP (NN upregulation) (NN p21)) (CC and/or) (NP (NN decrease) (NN survivin))) (, ,) (S (VP (VBG precipitating) (NP (NN growth) (NN arrest))))))))) |ET| |BS|45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 86:D01.268.556.435 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 5:1 18:1 19:1 23:1 36:1 102:1 149:1 264:1 295:1 299:1 464:1 602:1 691:1 1126:1 1135:1 2224:1 2225:1 2226:1 2227:1 2228:1 2229:1 2230:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN MTHFR) (NN genotype) (JJ relevant) (JJ independent) (NN factor) (NN patient) (NN outcome) (JJ 5FU-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 333:D01.045 396:G05.380 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 17:1 18:1 19:1 101:1 120:1 185:1 546:1 547:1 691:1 796:1 865:1 883:1 997:1 1329:1 2231:1 2232:1
-1 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD found) (NP (NP (JJ altered) (ADJP (QP (RB approximately) (CD 40)) (NN %)) (JJ rodent) (JJ chemically-induced) (NN liver) (NN tumor)) (, ,) (NP (NP (CD 40) (NN %)) (JJ human) (NN liver) (NN tumor)) (, ,) (NP (NN liver)) (, ,) (NP (NN kidney) (JJ pancreatic) (JJ human) (NN tumor) (NN cell) (NN line))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 242:A03.620 485:A05.810.453 514:B01.050.150.900.649.865 515:C04.588.274.623 607:A11.251.210.190 608:A03.734|ES| 2:1 7:1 9:1 19:1 36:1 37:1 94:1 264:1 369:1 467:1 582:1 691:1 693:1 836:1 1717:1 1805:1 1843:1 2173:1 2233:1
-1 	|BT| (NP (NP (NP (DT The) (NN transcription) (NN factor) (NNP LSF)) (: :) (NP (JJ novel) (NN oncogene) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|9:G05.360.340.024.340.375.500 104:C04.557.470.200.025.255 166:D12.776.930 259:D12.776.395.240.150.500|ES| 19:1 24:1 104:1 185:1 303:1 304:1 487:1 691:1 891:1 2150:1
-1 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1
-1 	|BT| (S (ADVP (RB Therefore)) (, ,) (VP (VBP conclude) (SBAR (S (NP (NP (NN miR-141) (NN target) (NN MAP4K4)) (, ,) (VP (VBP act) (NP (NN tumor) (NN suppressor) (JJ pancreatic) (NN cancer) (NN cell))) (, ,)) (VP (MD may) (VP (VB serve) (NP (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN agent) (JJ miRNA-based) (JJ pancreatic) (NN cancer) (NN therapy)))))))) |ET| |BS|41:A11 52:E02 81:E02.095.465.425.400.330.050.400 184:D13.150.650.319 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500 333:D01.045 557:D02.241.081.069.600.150|ES| 2:1 7:1 18:1 19:1 94:1 130:1 160:1 246:1 463:1 465:1 467:1 491:1 532:1 541:1 700:1 728:1 891:1 1620:1 1968:1 2234:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN HNF4alpha)) (VP (VBZ maintains) (NP (NP (NN hepatocyte) (NN differentiation) (JJ adult) (JJ healthy) (NN liver)) (, ,) (S (NP (NN loss)) (VP (MD may) (ADVP (RB directly)) (VP (VB contribute) (NP (JJ hepatocellular) (NN carcinoma) (NN development))) (, ,) (S (VP (ADVP (RB thus)) (VBG indicating) (NP (NN factor) (JJ possible) (NN liver) (NN tumor) (NN suppressor) (NN gene)))))))))))) |ET| |BS|74:G04.299.151 104:C04.557.470.200.025.255 119:M01.060.116 188:N02.628 206:G05.360.340.024.340.375.249 242:A03.620 262:A11.436.348 571:N01.400|ES| 2:1 7:1 9:1 19:1 32:1 35:1 123:1 185:1 215:1 303:1 304:1 355:1 450:1 491:1 621:1 631:1 700:1 792:1 793:1 796:1 836:1 1334:1 1359:1 1909:1 2235:1 2236:1
-1 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1
-1 	|BT| (S (NP (DT These) (NN study)) (VP (VB establish) (NP (NP (JJ key) (NN role) (NN LSF) (NN hepatocarcinogenesis) (NN usher) (JJ novel) (JJ therapeutic) (NN avenue)) (NP (NNP HCC))) (, ,) (NP (RB invariably) (JJ fatal) (NN disease)))) |ET| |BS|15:F01.829.316.616 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 288:C23.550.288|ES| 2:1 19:1 31:1 131:1 159:1 220:1 441:1 541:1 792:1 891:1 900:1 998:1 1655:1 2150:1 2237:1 2238:1 2239:1
-1 	|BT| (S (NP (NP (DT This) (JJ first) (NN study)) (VP (VBG showing) (NP (NN miR-205)))) (VP (VBZ inhibits) (NP (JJ proto-oncogenic) (NNS SFKs)) (, ,) (S (VP (VBG indicating) (NP (JJ therapeutic) (JJ potential) (NN miR-205) (NN treatment) (JJ renal) (NN cancer)))))) |ET| |BS|52:E02 122:C14.280.383 279:D27.888.569.100|ES| 2:1 18:1 19:1 131:1 541:1 546:1 615:1 807:1 816:1 827:1 922:1 2201:1 2236:1 2240:1 2241:1 2242:1
-1 	|BT| (S (NP (DT This)) (VP (VBD led) (SBAR (S (NP (NN u)) (VP (VBP investigate) (SBAR (S (NP (NP (JJ antitumor) (NN growth)) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin) (JJ immunocompetent) (NN xenograft) (NN model) (NN mouse) (JJ metastatic) (JJ mammary) (NN cancer) (NN p53) (NN mutation))) (VP (VBZ induces) (NP (NP (JJ metastatic) (NN spectrum)) (NP (JJ similar) (VBN seen) (JJ human) (NN breast) (NN cancer))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460|ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN inactivation) (NN TGF-beta) (NN signaling) (NN loss) (NN PTEN)) (VP (VBP cooperate) (NP (NP (NN drive) (JJ intestinal) (NN cancer) (NN formation) (NN progression)) (VP (VBG suppressing) (NP (NN cell) (NN cycle) (NN inhibitor)))))) |ET| |BS|16:C23.550.291.656 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 66:F01.658.293 69:G02.111.087.800 101:C04.588.274.476.411 353:G04.299.134 503:D12.644.276.374.687|ES| 2:1 18:1 19:1 32:1 43:1 48:1 94:1 109:1 181:1 195:1 380:1 474:1 601:1 1314:1 1691:1 1774:1 1936:1 2250:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN MYH11) (NN mutation)) (VP (VBP appear) (VP (VBP contribute) (ADVP (RB also)) (NP (JJ human) (JJ intestinal) (NN neoplasia))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411|ES| 2:1 5:1 19:1 34:1 36:1 109:1 450:1 640:1 1627:1 1691:1 2251:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PPARgamma1)) (VP (MD might) (VP (VB offer) (NP (JJ promising) (NN gene) (JJ therapeutic) (NN target) (NN atherosclerosis))))) |ET| |BS|52:E02 149:G05.360.340.024.340.364.875.890 511:C14.907.137.126.307 513:C14.907.137.126|ES| 2:1 9:1 19:1 160:1 541:1 798:1 1042:1 1517:1 1691:1 1803:1 1804:1
-1 	|BT| (S (S (VP (TO To) (VP (VB characterize) (NP (NN CC531) (NN model) (JJ molecular) (NN level))))) (, ,) (NP (VBN screened) (NN mutation) (NN gene)) (VP (VBG covering) (NP (NP (JJ important) (NN signal-transduction) (NN pathway)) (NP (NP (VBN known) (NN play) (JJ major) (NN role) (NN colon) (NN carcinogenesis)) (, ,) (NP (NN wnt) (JJ ki-ras) (NN signaling) (NN pathway)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 126:G02.111.087.800 611:E05.599.595|ES| 2:1 9:1 19:1 31:1 34:1 72:1 113:1 161:1 195:1 207:1 238:1 249:1 383:1 462:1 556:1 828:1 902:1 2252:1 2253:1 2254:1 2255:1 2256:1 2257:1 2258:1
-1 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (NN role) (NN APC) (NN gene) (NN microsatellite) (NN instability)) (PRN (-LRB- -LRB-) (NP (NN MI)) (-RRB- -RRB-))) (JJ PhIP-induced) (NN colon) (NN carcinogenesis))))) (, ,) (NP (NN mutation) (NN APC) (NN gene) (NN alteration) (NNS microsatellites)) (VP (VBN examined))) |ET| |BS|15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 394:G02.111.570.080.708.800.500 538:C23.550.362.590|ES| 2:1 9:1 10:1 11:1 14:1 19:1 31:1 34:1 113:1 207:1 324:1 459:1 828:1 951:1 1299:1 1332:1 1839:1 2259:1 2260:1
-1 	|BT| (NP (NP (NP (NNS Tumors)) (VP (VBG lacking) (S (NP (NN DNA) (NN mismatch) (NN repair) (NN activity) (-LRB- -LRB-) (NN MMR) (-RRB- -RRB-) (NN patient)) (NP (NP (NP (JJ Hereditary) (NN Nonpolyposis) (JJ Colorectal) (NN Cancer)) (PRN (-LRB- -LRB-) (NP (NN HNPCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ sporadic) (JJ colorectal) (NN cancer)) (VP (VBD identified) (NP (NP (NN presence) (JJ high) (NN level) (NN instability) (JJ repetitive) (NN sequence)) (VP (VBN known) (NP (NP (NNS microsatellites)) (PRN (-LRB- -LRB-) (NP (NN MSI)) (-RRB- -RRB-))))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 50:M01.643 174:G02.111.087.219.220 394:G02.111.570.080.708.800.500 524:C04.588.274.476.411.307.190 538:C23.550.362.590 612:G02.111.570.080.708|ES| 10:1 14:1 17:1 18:1 19:1 53:1 120:1 178:1 249:1 293:1 346:1 376:1 399:1 513:1 556:1 584:1 623:1 666:1 725:1 1299:1 1919:1 2134:1 2136:1 2260:1 2261:1 2262:1 2263:1 2264:1 2265:1
-1 	|BT| (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (NN Loss) (NN E-cadherin)) (PRN (-LRB- -LRB-) (NP (NN CDH1)) (-RRB- -RRB-))) (, ,) (NP (NN Smad4)) (, ,) (NP (NP (NN p53) (VBN shown) (NN play) (JJ integral) (NN role)) (ADJP (JJ gastric))) (, ,) (NP (JJ intestinal) (, ,) (NN breast) (NN cancer) (NN formation)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200|ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1
-1 	|BT| (S (NP (NP (NN Up-regulation) (JJ several) (NN miR-1) (NN target)) (PP (VBG including) (NP (NP (NN FoxP1)) (, ,) (NP (NN MET)) (, ,) (NP (NN HDAC4) (JJ primary) (JJ human) (NNS HCCs) (NP (NN down-regulation) (NN expression) (JJ 5-AzaC-treated) (NN HCC) (NN cell)))))) (VP (VBP suggest) (NP (NN role) (NN hepatocarcinogenesis)))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (NN cooperation) (NN RB) (NN p53) (NN liver) (NN development) (NN pathogenesis)) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 242:A03.620|ES| 12:1 19:1 35:1 303:1 304:1 501:1 836:1 843:1 1168:1 1209:1 1960:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NN parkin) (: -) (: /) (: -) (NP (NN mouse) (VBD enhanced) (NN hepatocyte) (NN proliferation)) (VP (VBD developed) (NP (JJ macroscopic) (JJ hepatic) (NN tumor) (JJ characteristic) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 262:A11.436.348 515:C04.588.274.623|ES| 7:1 19:1 52:1 299:1 303:1 304:1 336:1 385:1 838:1 843:1 1165:1 1175:1 1909:1 2275:1 2276:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB first)) (VP (VBP show) (SBAR (S (NP (NP (NN Notch-1) (NN receptor)) (, ,) (NP (ADJP (RB well) (JJ downstream)) (NN target) (NN Hes-1)) (, ,)) (VP (VBD up-regulated) (NP (NP (NN colon) (NN cancer) (NN progression)) (, ,) (NP (NP (JJ similar) (NN gene)) (VP (VBN involved) (S (NP (NN chemoresistance))))))))))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 142:I01.880.604 150:Z01.542.248.960|ES| 2:1 9:1 18:1 19:1 20:1 48:1 113:1 160:1 182:1 186:1 332:1 429:1 560:1 774:1 787:1 816:1 843:1 1301:1 2277:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (NP (NN enhancement) (NN Brf1) (NN Pol) (CD III) (NN gene) (NN expression)) (VBN associated) (NP (NP (NN occurrence) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 614:G05.360.340.024.340.364.875.667|ES| 9:1 10:1 14:1 19:1 52:1 115:1 169:1 303:1 304:1 441:1 843:1 1175:1 2278:1 2279:1 2280:1 2281:1 2282:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP document) (NP (NP (NN cooperation) (NN AEG-1) (NN c-Myc)) (VP (VBG promoting) (NP (NP (NN hepatocarcinogenesis) (VBG analyzing) (JJ hepatocyte-specific) (JJ transgenic) (NN mouse)) (VP (VBG expressing) (NP (CC either) (NP (NP (NN AEG-1)) (PRN (-LRB- -LRB-) (NP (NP (NN albumin)) (PRN (-LRB- -LSB-) (NP (NN Alb)) (-RRB- -RSB-))) (: /) (NP (NN AEG-1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN c-Myc)) (PRN (-LRB- -LRB-) (NP (NN Alb/c-Myc)) (-RRB- -RRB-))) (, ,)))))) (PRN (-LRB- -LRB-) (NP (NNP Alb/AEG) (CD -1) (: /) (NN c-Myc)) (-RRB- -RRB-)))) |ET| |BS|99:B01.050.050.136.500 262:A11.436.348 615:D12.776.034|ES| 2:1 10:1 14:1 19:1 39:1 52:1 285:1 810:1 824:1 843:1 881:1 900:1 1373:1 1378:1 1960:1 1976:1 2283:1 2284:1 2285:1 2286:1 2287:1 2288:1 2289:1 2290:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (NP (NP (JJ hepatic) (NN coexpression) (NN c-Myc) (NN E2F1)) (, ,) (NP (CD 2) (JJ key) (NN regulator) (NN proliferation) (NN apoptosis)) (, ,) (NP (VBD enhanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development) (JJ transgenic) (NN mouse))))) |ET| |BS|39:G04.299.139.160 99:B01.050.050.136.500 104:C04.557.470.200.025.255|ES| 2:1 10:1 14:1 19:1 35:1 52:1 89:1 148:1 159:1 235:1 285:1 299:1 303:1 304:1 385:1 441:1 824:1 838:1 843:1 993:1 1527:1 1961:1 2291:1
-1 	|BT| (NP (WHADVP (WRB When)) (NP (NP (NP (NN Apc) (NN gene) (NN knockout) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NN APC1309) (NN mouse)) (-RRB- -RRB-))) (VP (VBN given) (NP (CD 600) (CD 1200) (NN p.p.m))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 29:B01.050.050.136.500.500 193:C23.300.825.411 595:G07.203.650.240 596:E02.642.249 616:E05.318.780.074|ES| 2:1 5:1 9:1 10:1 14:1 19:1 29:1 52:1 71:1 109:1 170:1 202:1 280:1 289:1 369:1 370:1 646:1 647:1 781:1 783:1 2191:1 2292:1 2293:1 2294:1 2295:1 2296:1 2297:1 2298:1 2299:1 2300:1 2301:1
